- Home
- KPRX vs TRAW Comparison
KPRX vs TRAW Comparison
Compare KPRX & TRAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- TRAW
- Stock Information
- Founded
- KPRX 1998
- TRAW 1998
- Country
- KPRX United States
- TRAW United States
- Employees
- KPRX N/A
- TRAW N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- TRAW
- Sector
- KPRX Health Care
- TRAW
- Exchange
- KPRX Nasdaq
- TRAW NYSE
- Market Cap
- KPRX 8.3M
- TRAW 7.8M
- IPO Year
- KPRX N/A
- TRAW 2013
- Fundamental
- Price
- KPRX $3.13
- TRAW $1.10
- Analyst Decision
- KPRX Strong Buy
- TRAW
- Analyst Count
- KPRX 1
- TRAW 0
- Target Price
- KPRX $10.00
- TRAW N/A
- AVG Volume (30 Days)
- KPRX 12.7K
- TRAW 128.9K
- Earning Date
- KPRX 05-09-2025
- TRAW 05-15-2025
- Dividend Yield
- KPRX N/A
- TRAW N/A
- EPS Growth
- KPRX N/A
- TRAW N/A
- EPS
- KPRX N/A
- TRAW N/A
- Revenue
- KPRX $20,000.00
- TRAW $226,000.00
- Revenue This Year
- KPRX N/A
- TRAW $3.81
- Revenue Next Year
- KPRX N/A
- TRAW $30.43
- P/E Ratio
- KPRX N/A
- TRAW N/A
- Revenue Growth
- KPRX N/A
- TRAW N/A
- 52 Week Low
- KPRX $2.51
- TRAW $1.32
- 52 Week High
- KPRX $5.55
- TRAW $19.44
- Technical
- Relative Strength Index (RSI)
- KPRX 42.15
- TRAW 25.77
- Support Level
- KPRX $2.85
- TRAW $1.05
- Resistance Level
- KPRX $3.30
- TRAW $1.54
- Average True Range (ATR)
- KPRX 0.20
- TRAW 0.18
- MACD
- KPRX -0.02
- TRAW 0.02
- Stochastic Oscillator
- KPRX 16.34
- TRAW 20.63
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About TRAW TRAWS PHARMA INC
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.